Stroke Diagnostic and Therapeutic Market Report 2025

This stroke diagnostic and therapeutic market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The stroke diagnostic and therapeutic market size has grown strongly in recent years. It will grow from $33.41 billion in 2024 to $36.36 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to rising government funding and programs, development in access to healthcare services, rapid urbanization, growing better healthcare facilities, and the rapid expansion of telemedicine and tele-stroke services.

The stroke diagnostic and therapeutic market size is expected to see strong growth in the next few years. It will grow to $50.37 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to the surge in cases of diabetes, the rising number of patients with high blood pressure, increasing the number of patients at risk of developing stroke, raising awareness about stroke prevention, the increasing incidence and prevalence of stroke cases. Major trends in the forecast period include the increasing adoption of artificial intelligence (ai) and machine learning (ml) algorithms, advancement in power instruments, ongoing healthcare technology advancements, development in rapid and accurate diagnostic tools, and development in telemedicine and tele-stroke services.

The rising prevalence of stroke cases is anticipated to drive growth in the stroke diagnostic and therapeutic market. A stroke occurs when blood flow to a part of the brain is disrupted or reduced, depriving brain tissue of essential oxygen and nutrients, which can lead to brain cell damage or death. Hypertension increases stroke risk by damaging blood vessels, making them more prone to rupture or blockage. Effective stroke diagnostics and treatments are crucial, as prompt diagnosis and intervention can significantly mitigate brain damage, disability, and mortality. For example, a report by the American Heart Association in January 2024 indicated that stroke was responsible for 7.44 million deaths worldwide in 2021, including 3.71 million from ischemic stroke, 3.38 million from intracerebral hemorrhage, and 0.36 million from subarachnoid hemorrhage. Similarly, a report in January 2023 highlighted 7.08 million stroke-related deaths, with 3.48 million from ischemic stroke, 3.25 million from intracerebral hemorrhage, and 0.35 million from subarachnoid hemorrhage. Consequently, the growing incidence of stroke is fueling the expansion of the stroke diagnostic and therapeutic market.

Leading companies in the stroke diagnostic and therapeutic market are developing advanced AI-based healthcare platforms to enhance the precision and efficiency of stroke diagnosis and treatment. These AI-driven platforms analyze large volumes of patient data, identify patterns, and provide insights to improve diagnostic accuracy, treatment efficiency, and personalized care. For instance, RapidAI, a US-based AI technology provider, launched Rapid Edge Cloud in November 2023. This hybrid platform integrates cloud and on-premise technologies to boost speed, security, and flexibility. It seamlessly connects with hospital and third-party applications and has achieved Class III Shonin clearance in Japan, the world’s second-largest stroke market. Rapid Edge Cloud supports advanced stroke imaging and mechanical thrombectomy determination with unique MR-based perfusion capabilities. Its AI-powered non-contrast CT solutions, including Rapid NCCT Stroke, Rapid ASPECTS, Rapid Hypodensity, Rapid Hyperdensity, and Rapid SDH, are designed to detect potential stroke cases during initial CT scans, thus reducing decision-making and treatment times and improving patient outcomes.

In April 2022, Wallaby Medical Holding, Inc., a US-based developer of neurovascular interventional products for stroke treatment, acquired Phenox GmbH for $550 million. This acquisition expands Wallaby’s portfolio of neurovascular interventional products, particularly for ischemic and hemorrhagic stroke treatments. The integration of Phenox’s clinically proven technologies with Wallaby’s offerings will enable a more comprehensive range of solutions for healthcare providers. Phenox GmbH, based in Germany, specializes in technologies for treating neurovascular diseases such as ischemic and hemorrhagic strokes.

Major companies operating in the stroke diagnostic and therapeutic market are Johnson & Johnson Service Inc, Bayer AG, Abbott Laboratories, Medtronic plc, Boehringer Ingelheim International GmbH, Siemens Healthineers AG, Koninklijke Philips N. V., Stryker Corporation, GE HealthCare Technologies Inc., Boston Scientific Corporation, Terumo Corporation, Genentech Inc., Nihon Kohden Corporation, MicroPort Scientific Corporation, Penumbra Inc., ASAHI INTECC CO. LTD., Silk Road Medical Inc., RapidAI, Pharmazz Inc., Medfield Diagnostics AB, Perfuze Limited, Qure.ai Technologies Private limited.

North America was the largest region in the stroke diagnostic and therapeutic market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stroke diagnostic and therapeutic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the stroke diagnostic and therapeutic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Stroke diagnostics and therapeutics encompass the methods and treatments used to detect and manage strokes. Diagnostic techniques help visualize brain damage and identify the type of stroke, while therapeutic strategies focus on medical treatments and procedures to restore blood flow, minimize brain injury, and support patient rehabilitation. The goal is to quickly diagnose strokes and provide effective treatment to reduce long-term disability and improve recovery.

The primary categories in stroke diagnostics and therapeutics are diagnostics and therapeutics. Diagnostics involve tools and methods used to identify and evaluate strokes, which are essential for determining the stroke type and selecting appropriate treatments. Therapeutic strategies include stroke prevention methods such as medication management, lifestyle changes, and surgical interventions, applicable to various stroke types, including hemorrhagic and ischemic strokes.

The stroke diagnostic and therapeutic market research report is one of a series of new reports that provides stroke diagnostic and therapeutic market statistics, including the stroke diagnostic and therapeutic industry global market size, regional shares, competitors with the stroke diagnostic and therapeutic market share, detailed stroke diagnostic and therapeutic market segments, market trends, and opportunities, and any further data you may need to thrive in the stroke diagnostic and therapeutic industry. These stroke diagnostic and therapeutic market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The stroke diagnostic and therapeutic market consists of revenues earned by entities providing services such as telemedicine consultations, emergency stroke care, endovascular therapy, patient education and support programs, follow-up and monitoring, and pharmacotherapy management. The market value includes the value of related goods sold by the service provider or included within the service offering. The stroke diagnostic and therapeutic market also includes sales of mechanical thrombectomy devices, antiplatelet drugs, anticoagulants, and blood pressure monitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.